[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604206":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":26,"locations":33,"responsibleParty":100,"collaborators":7,"id":103,"slug":7,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":104,"sex":110,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":7,"studyType":116,"phases":7,"briefSummary":117,"conditions":118,"keywords":7,"overallStatus":36,"whyStopped":7,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"Universita degli Studi di Genova","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Esketamine (Intranasal Spray)","Esketamine Intranasal Spray at a dosage ranging from 28 to 84 mg weekly, with twice-weekly administration during the first month of treatment, according to the approved labeling",[14,18,20,23],{"name":15,"affiliation":16,"role":17},"Elisa Briasco, MD","Unige","PRINCIPAL_INVESTIGATOR",{"name":19,"affiliation":16,"role":17},"Elisa Cavanna, MD",{"name":21,"affiliation":16,"role":22},"Riccardo Guglielmo, MD","STUDY_CHAIR",{"name":24,"affiliation":16,"role":25},"Gianluca Serafini, MD","STUDY_DIRECTOR",[27,31],{"name":21,"role":28,"phone":29,"phoneExt":7,"email":30},"CONTACT","+390105552202","riccardo.guglielmo@unige.it",{"name":19,"role":28,"phone":29,"phoneExt":7,"email":32},"elisa.cavanna01@gmail.com",[34,50,61,75,89],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Ospedale Policlinico San Martino","RECRUITING","Genova","Ge","16132","Italy",{"type":42,"coordinates":43},"Point",[44,45],11.87211,45.21604,{"lat":45,"lon":44},[48],{"name":49,"role":28,"phone":7,"phoneExt":29,"email":30},"Riccardo Guglielmo",{"facility":51,"status":36,"city":37,"state":38,"zip":52,"country":40,"cosmosGeoPoint":53,"geoPoint":55,"contacts":56},"Csm Dds 8","16158",{"type":42,"coordinates":54},[44,45],{"lat":45,"lon":44},[57],{"name":58,"role":28,"phone":59,"phoneExt":7,"email":60},"Daniela Malagamba, MD","+390108499160","daniela.malagamba@asl3.liguria.it",{"facility":62,"status":36,"city":63,"state":7,"zip":64,"country":40,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Università di Chieti","Chieti","66100",{"type":42,"coordinates":66},[67,68],14.16494,42.34827,{"lat":68,"lon":67},[71],{"name":72,"role":28,"phone":73,"phoneExt":7,"email":74},"Giovanni Martinotti, Ph.D","+3908713551","giovanni.martinotti@unich.it",{"facility":76,"status":36,"city":77,"state":7,"zip":78,"country":40,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"ASST Fatebenefratelli Sacco","Milan","20157",{"type":42,"coordinates":80},[81,82],12.59836,42.78235,{"lat":82,"lon":81},[85],{"name":86,"role":28,"phone":87,"phoneExt":7,"email":88},"Miriam Olivola, Investigator","+390239042904","miriamolivola@icloud.com",{"facility":90,"status":36,"city":91,"state":7,"zip":92,"country":40,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"ASST Pavia","Pavia","27100",{"type":42,"coordinates":94},[95,96],9.15917,45.19205,{"lat":96,"lon":95},[99],{"name":86,"role":28,"phone":87,"phoneExt":7,"email":88},{"type":101,"investigatorFullName":49,"investigatorTitle":102,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Principal Investigator","100604206",false,"NCT07146503","Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression","ESKPSY: Esketamine in Real-World Settings: Clinical Outcomes, Predictors of Response, Life Functioning and Biological Pathways","ESKPSY","Inclusion criteria were: (a) age 18-74, (b) DSM-5 diagnosis of a major depressive episode (MDE), (c) failure to respond to at least 2 prior antidepressant treatments (ADTs), and (d) current treatment with an SSRI or SNRI for which esketamine nasal spray was deemed appropriate.","ALL","18 Years","74 Years",{"count":114,"type":115},100,"ESTIMATED","OBSERVATIONAL","This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings. The study aims to evaluate the clinical outcomes, including efficacy and safety, of esketamine treatment. It also explores predictors of treatment response, focusing on biological pathways such as genetics, neuroimaging, and psychophysical measures. Additionally, the study examines how esketamine impacts patients' life functioning, including social and occupational aspects. The goal is to better understand who benefits most from esketamine and how it affects daily life, to improve personalized care for patients with difficult-to-treat depression.",[119,120,121,122,123,124,125,126],"Depression and Quality of Life","Treatment Resistant Depression (TRD)","Anhedonia","Apathy","Anxiety","Cognition","Temperament","Psychiatric Comorbidities","2026-03-25",{"date":129,"type":130},"2026-03-31","ACTUAL",{"date":132,"type":130},"2022-11-01",{"date":134,"type":115},"2030-08",{"name":49,"class":6},5]